Tiziana Management Team to Attend the 10th Joint ACTRIMS-ECTRIMS Meeting in TorontoGlobeNewsWire · 5 days ago
Tiziana completes dosing in Phase 2 Alzheimer's trial of intranasal foralumabProactive Investors · Oct 16, 2026
Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer's DiseaseGlobeNewsWire · Oct 16, 2026
Tiziana Life Sciences seeks FDA orphan drug status for nasal MSA therapyProactive Investors · Sep 30, 2026
Tiziana doses first three patients in ALS trial of nasal antibody foralumabProactive Investors · Sep 28, 2026
Tiziana Life Sciences completes patient visits in Phase 2a MS drug trialProactive Investors · Sep 21, 2026Tiziana Life Sciences Ltd is a biotechnology firm dedicated to the research and advancement of novel molecular therapies for human ailments, particularly within oncology and immunology. Its flagship immunology program features Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody under development for a range of conditions including Crohn's disease, graft versus host disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Additionally, the company is progressing Milciclib (TZLS-201), a small molecule inhibitor that targets multiple cyclin-dependent, tropomycin receptor, and Src family kinases to suppress abnormal cell growth and cancer progression.